These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 36366508)
1. Recombinant Virus-like Particles of Human Parvovirus B19 with the Internal Location of VP1 Unique Region Produced by Shao S; Wang Q; Jin Y; Zhang X; Liu Z; Chen S; Wu H; Yang S; Tang F; Su J; Liang Y; Zhang J; Li Q Viruses; 2022 Oct; 14(11):. PubMed ID: 36366508 [TBL] [Abstract][Full Text] [Related]
3. [Genetic diversity of human Parvovirus B19 VP1 unique region]. Qian XH; Zhang GC; Jiao XY; Zhang P; Sun X; Cao YH; Xu DL; Fei LL; Huang WJ Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):128-30. PubMed ID: 14759319 [TBL] [Abstract][Full Text] [Related]
4. In vitro refolding of the structural protein VP1 of parvovirus B19 produces virus-like particles with functional VP1 unique region. Soto-Valerio IA; Cayetano-Cruz M; Valadez-García J; Guadarrama P; Méndez C; Bustos-Jaimes I Virology; 2022 May; 570():57-66. PubMed ID: 35367742 [TBL] [Abstract][Full Text] [Related]
5. Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells. Michel PO; Mäkelä AR; Korhonen E; Toivola J; Hedman L; Söderlund-Venermo M; Hedman K; Oker-Blom C J Virol Methods; 2008 Sep; 152(1-2):1-5. PubMed ID: 18598721 [TBL] [Abstract][Full Text] [Related]
6. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. Rosenfeld SJ; Yoshimoto K; Kajigaya S; Anderson S; Young NS; Field A; Warrener P; Bansal G; Collett MS J Clin Invest; 1992 Jun; 89(6):2023-9. PubMed ID: 1376332 [TBL] [Abstract][Full Text] [Related]
7. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors. Lowin T; Raab U; Schroeder J; Franssila R; Modrow S J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399 [TBL] [Abstract][Full Text] [Related]
8. Structure of Parvovirus B19 Decorated by Fabs from a Human Antibody. Sun Y; Klose T; Liu Y; Modrow S; Rossmann MG J Virol; 2019 May; 93(9):. PubMed ID: 30787153 [TBL] [Abstract][Full Text] [Related]
9. Subunit interaction in B19 parvovirus empty capsids. Rosenfeld SJ; Young NS; Alling D; Ayub J; Saxinger C Arch Virol; 1994; 136(1-2):9-18. PubMed ID: 7516147 [TBL] [Abstract][Full Text] [Related]
10. Stability and integrity of self-assembled bovine parvovirus virus‑like particles (BPV‑VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment. Wubshet AK; Li GX; Li Q; Dai JF; Ding YZ; Zhou L; Qu M; Wang Y; Ma Z; Werid GM; Abera BH; Kebede AT; Sun Y; Yin X; Liu Y; Jie Z Virol J; 2024 Apr; 21(1):87. PubMed ID: 38641833 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity. Suzuki H; Noguchi T; Matsugu N; Suzuki A; Kimura S; Onishi M; Kosaka M; Miyazato P; Morita E; Ebina H Vaccine; 2022 Oct; 40(42):6100-6106. PubMed ID: 36114131 [TBL] [Abstract][Full Text] [Related]
13. Reduction of Postweaning Multisystemic Wasting Syndrome-Associated Clinical Symptoms by Virus-Like Particle Vaccine Against Porcine Parvovirus and Porcine Circovirus Type 2. Liu G; Qiao X; Chang C; Hua T; Wang J; Tang B; Zhang D Viral Immunol; 2020; 33(6):444-456. PubMed ID: 32255758 [TBL] [Abstract][Full Text] [Related]
14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
15. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19. Franssila R; Hedman K Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. Saikawa T; Anderson S; Momoeda M; Kajigaya S; Young NS J Virol; 1993 Jun; 67(6):3004-9. PubMed ID: 7684458 [TBL] [Abstract][Full Text] [Related]
17. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. Kerr S; O'Keeffe G; Kilty C; Doyle S J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405 [TBL] [Abstract][Full Text] [Related]
18. Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation. Wang J; Liu Y; Chen Y; Wang A; Wei Q; Liu D; Zhang G Appl Microbiol Biotechnol; 2020 May; 104(9):3847-3857. PubMed ID: 32130468 [TBL] [Abstract][Full Text] [Related]
19. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. Gigler A; Dorsch S; Hemauer A; Williams C; Kim S; Young NS; Zolla-Pazner S; Wolf H; Gorny MK; Modrow S J Virol; 1999 Mar; 73(3):1974-9. PubMed ID: 9971777 [TBL] [Abstract][Full Text] [Related]
20. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Kajigaya S; Fujii H; Field A; Anderson S; Rosenfeld S; Anderson LJ; Shimada T; Young NS Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4646-50. PubMed ID: 1711206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]